Renata enters Canadian market with oral contraceptive launch
Renata PLC has launched its first Canadian product: Desogestrel/Ethinylestradiol (0.15mg/0.03mg) tablets.
The oral contraceptive combines Desogestrel, a progestin, with Ethinylestradiol, an oestrogen, in a fixed-dose formulation. It is manufactured at Renata's Health Canada-approved potent product facility and will be commercialised through a strategic partnership with Ambicare Pharmaceuticals Inc under the brand names Miley 21 and Miley 28.
Ambicare Pharmaceuticals, a Canadian generic pharmaceutical company, is recognised for its portfolio of high-quality, niche products spanning multiple therapeutic areas. Renata also markets the same formulation in Bangladesh under the brand name Desolon.
Keep updated, follow The Business Standard's Google news channel
Entering the Canadian pharmaceutical market marks a milestone for Renata, as it aims to build on past successes by expanding its portfolio in Canada.
